Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells

Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):19854-19865. doi: 10.1073/pnas.1911532117. Epub 2020 Aug 5.

Abstract

The blood-retina barrier and blood-brain barrier (BRB/BBB) are selective and semipermeable and are critical for supporting and protecting central nervous system (CNS)-resident cells. Endothelial cells (ECs) within the BRB/BBB are tightly coupled, express high levels of Claudin-5 (CLDN5), a junctional protein that stabilizes ECs, and are important for proper neuronal function. To identify novel CLDN5 regulators (and ultimately EC stabilizers), we generated a CLDN5-P2A-GFP stable cell line from human pluripotent stem cells (hPSCs), directed their differentiation to ECs (CLDN5-GFP hPSC-ECs), and performed flow cytometry-based chemogenomic library screening to measure GFP expression as a surrogate reporter of barrier integrity. Using this approach, we identified 62 unique compounds that activated CLDN5-GFP. Among them were TGF-β pathway inhibitors, including RepSox. When applied to hPSC-ECs, primary brain ECs, and retinal ECs, RepSox strongly elevated barrier resistance (transendothelial electrical resistance), reduced paracellular permeability (fluorescein isothiocyanate-dextran), and prevented vascular endothelial growth factor A (VEGFA)-induced barrier breakdown in vitro. RepSox also altered vascular patterning in the mouse retina during development when delivered exogenously. To determine the mechanism of action of RepSox, we performed kinome-, transcriptome-, and proteome-profiling and discovered that RepSox inhibited TGF-β, VEGFA, and inflammatory gene networks. In addition, RepSox not only activated vascular-stabilizing and barrier-establishing Notch and Wnt pathways, but also induced expression of important tight junctions and transporters. Taken together, our data suggest that inhibiting multiple pathways by selected individual small molecules, such as RepSox, may be an effective strategy for the development of better BRB/BBB models and novel EC barrier-inducing therapeutics.

Keywords: CLDN5; chemogenomic library; endothelial cell barrier; genome editing; human pluripotent stem cell-derived endothelial cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Blood-Retinal Barrier / drug effects
  • Blood-Retinal Barrier / metabolism
  • Cell Differentiation
  • Cell Line
  • Cell Proliferation / drug effects
  • Claudin-5 / genetics
  • Claudin-5 / metabolism
  • Drug Evaluation, Preclinical
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Gene Editing
  • Genome
  • Humans
  • Mice
  • Mice, Knockout
  • Pluripotent Stem Cells / cytology
  • Pluripotent Stem Cells / drug effects*
  • Pluripotent Stem Cells / metabolism
  • Pyrazoles / pharmacology
  • Pyridines / pharmacology
  • Small Molecule Libraries / pharmacology*
  • Tight Junctions / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Claudin-5
  • Pyrazoles
  • Pyridines
  • RepSox
  • Small Molecule Libraries
  • Vascular Endothelial Growth Factor A